NEP Enzyme Activity Increases in Heart Failure, Potentially Limiting Protective Peptide Effects | Research

The takeaway

In a volume-overload heart failure model, NEP activity is increased alongside elevated natriuretic peptides, suggesting the enzyme limits the protective effects of these cardiac peptides.

NEP increases in heart failure
NEP activity rose alongside natriuretic peptides, suggesting it limits their protective effects in a vicious cycle

What the researchers found

NEP activity is increased in volume-overload heart failure, potentially accelerating the breakdown of protective natriuretic peptides even as the heart produces more of them.

Why it matters

If NEP destroys protective peptides faster in heart failure, inhibiting NEP could restore the balance between vasodilator and vasoconstrictor forces — a key therapeutic principle.

How the study worked

Aortovenocaval fistula rat model of heart failure with measurement of NEP activity, natriuretic peptide levels, and renin-angiotensin-aldosterone system activation.

What this study cannot tell us

Surgical animal model that may not fully represent human chronic heart failure. NEP activity measurement may not reflect tissue-specific activity.

How to read the evidence

Moderate animal evidence from a well-established heart failure model. Provides pathophysiological insight supporting NEP inhibitor therapy.

When this study was published

Published in 1996, contributing to the growing evidence that led to sacubitril development for heart failure.

The bigger picture

This study revealed a vicious cycle in heart failure where the enzyme that destroys protective peptides increases alongside the peptides themselves, providing further rationale for NEP inhibitor therapy.

Questions still open

Does NEP inhibition restore natriuretic peptide levels in heart failure?
Is increased NEP activity a cause or consequence of heart failure progression?

Common questions

What happens to natriuretic peptides in heart failure?

The heart produces more ANP and BNP as it struggles, trying to lower blood pressure and reduce fluid overload. But this study shows the enzyme that destroys them (NEP) also increases, creating a futile cycle where the body can't get enough benefit from its own protective peptides.

How does this explain why Entresto works?

By blocking NEP, sacubitril (in Entresto) stops the enzyme from destroying natriuretic peptides. In heart failure, where NEP activity is already elevated, this intervention restores the protective peptide effects the heart is desperately trying to achieve.

Read the original research

Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.

Cardiovascular research, 31(6), 891-8

View on PubMed ↗

Citation

Wegner, M; Hirth-Dietrich, C; Stasch, J P. (1996). Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.. Cardiovascular research, 31(6), 891-8.